Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
( DrugBank: Alemtuzumab, Melphalan, Fludarabine, Thiotepa / KEGG DRUG: Alemtuzumab, Melphalan, Melphalan hydrochloride, Fludarabine phosphate, Fludarabine, Thiotepa )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 65 | Primary immunodeficiency | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 164 | Oculocutaneous albinism | 1 |
65. Primary immunodeficiency
Clinical trials : 866 / Drugs : 858 - (DrugBank : 122) / Drug target genes : 108 - Drug target pathways : 232
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
164. Oculocutaneous albinism
Clinical trials : 17 / Drugs : 57 - (DrugBank : 32) / Drug target genes : 32 - Drug target pathways : 139
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|